Trials / Terminated
TerminatedNCT03569033
Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)
A Phase 2a, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of MK-7264 on Acute Cough in Participants With Induced Viral Upper Respiratory Tract Infection
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of gefapixant (MK-7264) in adult participants with induced viral upper respiratory tract infections (URTI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefapixant | Gefapixant 45 mg will be administered orally. |
| DRUG | Placebo | Placebo tablet matching gefapixant will be administered orally. |
Timeline
- Start date
- 2018-07-04
- Primary completion
- 2018-10-31
- Completion
- 2018-11-19
- First posted
- 2018-06-26
- Last updated
- 2019-12-10
- Results posted
- 2019-12-10
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03569033. Inclusion in this directory is not an endorsement.